Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”The first generation of hemophilia A gene therapies changed the field in an important way.
The question is no longer simply whether gene therapy can reduce bleeding.
The question is whether gene therapy can deliver durable expression over time.
Patients remain highly interested in gene therapy, but long-term durability has become central to adoption decisions for both patients and providers.
At GeneVentiv, this understanding shaped the design and program development of GENV-HEM (AAV8.FVa), which leverages native hepatic biology associated with Factor V expression.
Importantly, our vision for the future of hemophilia A gene therapy includes inhibitor patients.
Patient decisions to adopt gene therapy will ultimately be made not just by efficacy, but by durability.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 01:27X. Long Zheng: Optimizing Treatment in Immune TTP
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C